Soft drug-inhibitors for the epigenetic targets Lysine-Specific Demethylase 1 (LSD1) and Histone Deacetylases (HDACs)

02 May 2022, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Epigenetic modulators such as Lysine-specific Demethylase 1 (LSD1) and Histone Deacetylases (HDACs), are drug targets for cancer, neuropsychatric disease or inflammation but inhibitors of these enzymes exhibit considerable side effects. For a potential local treatment with reduced systemic toxicity, we present here soft drugs as new LSD1 and HDAC inhibitors. A soft drug is a compound that is degraded in vivo to less active metabolites, after having achieved its therapeutic function. This has been successfully applied for corticosteroids in the clinic but soft drugs targeting epigenetic enzymes are scarce, with the HDAC inhibitor remetinostat being the only example. We have developed new methyl ester containing inhibitors targeting LSD1 respectively HDACs and compared their biological activity to the one of their respective carboxylic acids cleavage products. In vitro activity assays, cellular experiments, and a stability assay identified potent HDAC and LSD1 soft drugs that are superior to their corresponding carboxylic acids as potential candidates for local therapy with minimized side effects.

Keywords

epigenetics
HDACs
LSD1
histone deacetylase
histone demethylase
soft drugs

Supplementary materials

Title
Description
Actions
Title
Supplemental material
Description
HPLC traces
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.